BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/20/2025 8:41:23 AM | Browse: 100 | Download: 383
 |
Received |
|
2025-03-10 05:59 |
|
Peer-Review Started |
|
2025-03-10 05:59 |
|
First Decision by Editorial Office Director |
|
2025-04-09 10:58 |
|
Return for Revision |
|
2025-04-09 11:37 |
|
Revised |
|
2025-04-23 09:46 |
|
Publication Fee Transferred |
|
2025-04-24 03:23 |
|
Second Decision by Editor |
|
2025-06-24 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-06-24 08:00 |
|
Articles in Press |
|
2025-06-24 08:00 |
|
Edit the Manuscript by Language Editor |
|
2025-07-01 19:30 |
|
Typeset the Manuscript |
|
2025-08-06 06:53 |
|
Publish the Manuscript Online |
|
2025-08-20 08:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ting Zheng, Xing-Xing Li, Li Zhou and Jian-Jiang Jin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ting Zheng, Department of Medical Oncology, The First People’s Hospital of Linping District, No. 369 Yingbin Road, Linping District, Hangzhou 311100, Zhejiang Province, China. zz_tt666@163.com |
| Key Words |
Programmed death 1 or its ligand; Standard-of-care; Metastatic colorectal cancer; First-line; Meta-analysis |
| Core Tip |
We performed a meta-analysis to evaluate the therapy and safety of combining programmed death 1 or its ligand inhibitors with standard-of-care therapy as first-line treatment for metastatic colorectal cancer. Results showed integrating programmed death 1 or its ligand inhibitors with standard-of-care regimens for metastatic colorectal cancer as first-line treatment failed to demonstrate significant improvements in overall response rate. Existing clinical data remain inadequate to establish overall survival advantages, particularly in patients with microsatellite stable/mismatch repair-proficient, despite exhibiting manageable toxicity profiles. |
| Publish Date |
2025-08-20 08:41 |
| Citation |
Zheng T, Li XX, Zhou L, Jin JJ. Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis. World J Clin Oncol 2025; 16(8): 106873 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i8/106873.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i8.106873 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
